A phase II trial of deoxyspergualin in recurrent squamous cell head and neck cancer. Academic Article uri icon

Overview

abstract

  • Fifteen patients with recurrent squamous cell head and neck cancer were treated with deoxyspergualin. There were no objective responses in 14 evaluable patients. The most common toxicity was reversible hypotension, which prompted dose reduction in nine patients. Deoxyspergualin is not recommended for the treatment of squamous cell head and neck cancer.

publication date

  • February 1, 1993

Research

keywords

  • Antibiotics, Antineoplastic
  • Carcinoma, Squamous Cell
  • Drugs, Investigational
  • Guanidines
  • Head and Neck Neoplasms
  • Neoplasm Recurrence, Local

Identity

Scopus Document Identifier

  • 0027324724

PubMed ID

  • 8349436

Additional Document Info

volume

  • 11

issue

  • 1